Keyphrases
Cyclophosphamide
100%
Prednisolone
100%
Serum Interleukins
100%
Interleukin-18 (IL-18)
100%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Rituximab
100%
Doxorubicin
100%
Progression-free Survival
50%
Overall Survival Rate
33%
Clinical Outcomes
16%
Multivariate Analysis
16%
Poor Prognosis
16%
Prognostic Factors
16%
Lymphoma Patients
16%
Prognostic Significance
16%
B Cell Phenotype
16%
Poor Prognostic
16%
Germinal Center B Cells
16%
Non-germinal Centre
16%
Aggressive non-Hodgkin Lymphoma
16%
Prognostic Groups
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Diffuse Large B Cell Lymphoma
100%
Rituximab
100%
Prednisolone
100%
Doxorubicin
100%
Vincristine
100%
Interleukin 18
100%
Progression Free Survival
50%
Survival Rate
33%
Overall Survival
33%
Nonhodgkin Lymphoma
16%
Immunology and Microbiology
B Cell
100%
Interleukin 18
100%
Cyclophosphamide
100%
Rituximab
100%
Prednisolone
100%
Progression Free Survival
50%
Survival Rate
33%
Overall Survival
33%
Germinal Center
16%